Browse Category

Pharmaceuticals 17 November 2025 - 22 November 2025

Pfizer (PFE) Stock Rallies on November 21, 2025 as Investors Focus on FDA Win, Obesity Pivot and 7% Dividend Yield

Pfizer finished Friday’s session on a strong note, with the stock climbing as investors digested a fresh U.S. FDA approval in bladder cancer, progress in obesity drugs, a multi‑billion‑dollar bond sale and one of the highest dividend yields among mega‑cap healthcare names.

22 November 2025

NYSE:PFE·Pfizer·Pharmaceuticals

Merck (MRK) Stock Today: Mini‑Tender Warning, Dividend Hike and Drug Wins – 22 November 2025

Merck & Co., Inc. is firmly in the spotlight this weekend as the U.S. pharma giant juggles shareholder protection, a higher dividend, and fresh regulatory wins — all while its share price trades near the upper end of its 12‑month range.

22 November 2025

Dividends·NYSE:MRK·Pharmaceuticals·Stock Market

Novo Nordisk Stock on 21 November 2025: NVO Slips as Denmark Grants Eye-Damage Payouts and GLP‑1 Price War Escalates

As of late morning in New York, Novo Nordisk’s U.S. ADR is trading around $47.07, down roughly 1.1% on the day, giving the company a market value close to $213 billion. In Copenhagen, Novo Nordisk’s B‑shares finished the session around DKK 305, down nearly 3% and extending a steep slide that has left the stock down about 45% year‑to‑date. Investing.com+1

21 November 2025

CSE:NOVOB·NYSE:NVO·Pharmaceuticals·Stock Market

Pfizer Stock Today (PFE): mRNA Flu Breakthrough, $6B Metsera Bonds and a 7% Dividend – Nov. 21, 2025

Pfizer’s share price is back in the spotlight on Friday, November 21, 2025, as investors digest strong Phase 3 flu-vaccine data, a $6 billion bond sale to fund its obesity-drug deal, and ongoing debate around the company’s roughly 7% dividend yield.

21 November 2025

Dividends·NYSE:PFE·Pharmaceuticals·Stock Market

Telomir Pharmaceuticals (TELO) Unveils Leukemia Breakthrough and Board Change – Full Investor Update for November 21, 2025

Telomir Pharmaceuticals shares react to new preclinical leukemia data and a director resignation on November 21, 2025. Here’s what today’s Telomir-1 news means for TELO stock and investors.

21 November 2025

Biotechnology·NASDAQ:TELO·Pharmaceuticals

Pfizer Stock Today, November 20, 2025: Price Slide, Dividend Debate, Flu Shot Win and Texas Settlement

Pfizer stock spent most of Thursday in the red as investors weighed a near‑7% dividend yield against fresh legal headlines, new R&D wins and ongoing questions about the company’s post‑COVID growth story.

20 November 2025

Dividends·NYSE:PFE·Pharmaceuticals·Stock Market

Moderna (MRNA) Sets 3‑Year mRNA Growth Plan After $1.5 Billion Loan and $140 Million U.S. Expansion – November 20, 2025

Moderna secured a $1.5 billion Ares loan, outlined a three‑year strategy targeting up to 10% revenue growth in 2026, and confirmed a $140 million U.S. manufacturing expansion as it races toward cash breakeven by 2028.

20 November 2025

Biotechnology·NASDAQ:MRNA·Pharmaceuticals

Psyence BioMed (NASDAQ: PBM) Jumps as It Secures Pharmaceutical‑Grade Ibogaine Supply for Global Clinical Trials – 20 November 2025

Psyence Biomedical Ltd. is back in the spotlight today after announcing a “major breakthrough” in its ibogaine supply chain and emerging as one of the more active healthcare micro‑caps in pre‑market trading.

20 November 2025

Biotechnology·NASDAQ:PBM·Pharmaceuticals·Stock Market

Novo Nordisk Stock Today (November 20, 2025): Wegovy Price Cuts, Alzheimer’s ‘Lottery Ticket’ Trials and Denmark GDP Put NVO Back in the Spotlight

Novo Nordisk stock is back on traders’ screens today as a cluster of fresh headlines – from high‑stakes Alzheimer’s trials to aggressive Wegovy price cuts and new Danish GDP data – reshapes the narrative around the Ozempic maker.

20 November 2025

CSE:NOVO-B.CO·NYSE:NVO·Pharmaceuticals·Stock Market

RANI Stock Today (Nov 19, 2025): Rani Therapeutics slips to $1.75 as traders weigh October’s Chugai deal and year‑end catalysts

Rani Therapeutics Holdings finished Wednesday, Nov. 19, 2025 at $1.75, down from $1.86 on Tuesday. The stock opened at $1.83, traded between $1.70–$1.90, and moved ~2.5M shares on the day, according to end‑of‑day pricing data. Yahoo Finance

20 November 2025

NASDAQ:RANI·Pharmaceuticals·Stock Market

Agios Pharmaceuticals (AGIO) Stock Slides on Mixed Phase 3 Sickle Cell Results From RISE UP Trial

Agios Pharmaceuticals, Inc. is in the spotlight today after unveiling topline results from its pivotal Phase 3 RISE UP trial of mitapivat in sickle cell disease — data that are being widely described as “mixed” and have sent the stock sharply lower. GlobeNewswire+2Reuters+2

19 November 2025

NASDAQ:AGIO·Pharmaceuticals·Stock Market

KVUE Stock Today (Nov. 18, 2025): Shares Slip as Appeals Court Weighs Tylenol Cases; Dividend Cleared; Kimberly‑Clark Deal Spread Persists

KVUE softened today after Monday’s developments in federal litigation tied to claims that prenatal acetaminophen use raises autism risk. A three‑judge appeals panel questioned the lower court’s dismissal of those cases, opening the door to their potential return and keeping headline risk front‑and‑center for the stock. Reuters

18 November 2025

Dividends·Mergers & Acquisitions·NYSE:KMB·NYSE:KVUE·Pharmaceuticals·Stock Market

Arvinas (ARVN) Soars 14% as Investors Cheer Pipeline Reset and Jefferies Update

Arvinas jumped in double digits on November 18, 2025 amid a focused pipeline reset, FDA momentum for vepdegestrant and attention at the Jefferies London Healthcare Conference.

18 November 2025

NASDAQ:ARVN·Pharmaceuticals·Stock Market

Novo Nordisk Stock Today (Nov 18, 2025): $199 Wegovy/Ozempic Intro Offer Drives Focus; Controlling Shareholder Sells ConvaTec Stake; NVO Edges Lower

Summary: Novo Nordisk remains in the spotlight after rolling out a U.S. self‑pay price cut for Wegovy and Ozempic—plus a two‑month $199 introductory offer for new patients—while its controlling shareholder Novo Holdings exited its ConvaTec stake in London. U.S.-listed shares were modestly lower intraday as investors weighed near‑term pricing pressure against potential volume gains and ongoing governance/pipeline developments. Reuters+2NovoCare+2

18 November 2025

NYSE:NVO·Pharmaceuticals·Stock Market

Merck (MRK) Stock Today, Nov 18, 2025: Shares Jump on Winrevair Phase 2 Win as Cidara Deal Builds Flu Portfolio

November 18, 2025 — Merck & Co. is trading higher today after the company reported new mid‑stage data for its cardiopulmonary medicine Winrevair, fueling optimism about growth beyond Keytruda and adding momentum to last week’s acquisition of Cidara Therapeutics. Merck.com+1

18 November 2025

NYSE:MRK·Pharmaceuticals·Stock Market

Olema Pharmaceuticals (OLMA) Soars Over 200% After Roche Breast Cancer Trial Win — What It Means for Palazestrant and Investors on November 18, 2025

Olema Pharmaceuticals didn’t publish a press release or file anything with the SEC this morning. Yet, its stock rocketed nearly threefold in pre‑market trading on Tuesday, November 18, 2025. TipRanks+1

18 November 2025

Biotechnology·NASDAQ:OLMA·NYSE:PFE·Pharmaceuticals·Stock Market·SWX:ROG.SW

Pfizer (PFE) Stock Today, November 17, 2025: Migraine Drug Launch in India, Metsera Deal Closes and New RSV Vaccine Data

Pfizer Inc. is back in the headlines today with a flurry of developments that span new product launches, obesity-drug M&A, fresh vaccine data and ongoing debate about whether its battered stock is finally a buy.

17 November 2025

NYSE:PFE·Pharmaceuticals·Stock Market

Tonix Pharmaceuticals (TNXP) Jumps as TONMYA, First New Fibromyalgia Drug in 15 Years, Hits U.S. Pharmacies – November 17, 2025

Tonix Pharmaceuticals Holding Corp. moved sharply higher today after the company confirmed that TONMYA™, its newly approved fibromyalgia treatment, is now commercially available by prescription across the United States.GlobeNewswire+1

17 November 2025

Healthcare News·NASDAQ:TNXP·Pharmaceuticals

Galmed Pharmaceuticals (GLMD) Soars on New Cancer Drug Combo Data: What Today’s Breakthrough Means for Investors – November 17, 2025

As of this afternoon, Galmed Pharmaceuticals shares were changing hands around $1.18, up roughly 13% on the day, with more than 41 million shares traded—massively above the stock’s usual daily volume. TipRanks

17 November 2025

Biotechnology·NASDAQ:GLMD·Pharmaceuticals·Stock Market

Jazz Pharmaceuticals (JAZZ) Soars on Breakthrough Ziihera Phase 3 Results in Gastroesophageal Cancer – Key Updates for 17 November 2025

Jazz Pharmaceuticals plc is in the spotlight today after announcing positive Phase 3 data for its cancer drug Ziihera® in a large global trial for HER2‑positive gastroesophageal adenocarcinoma. The news has triggered sharp pre‑market moves in Jazz’s share price and its partners’ stocks, and could reshape the treatment landscape for a difficult‑to‑treat cancer. PR Newswire+1

17 November 2025

Healthcare News·NASDAQ:JAZZ·NASDAQ:ZYME·Pharmaceuticals

Previous 1 … 39 40 41 42 43 … 47 Next

Pharmaceuticals 17 November 2025 - 22 November 2025

Pfizer (PFE) Stock Rallies on November 21, 2025 as Investors Focus on FDA Win, Obesity Pivot and 7% Dividend Yield

Merck (MRK) Stock Today: Mini‑Tender Warning, Dividend Hike and Drug Wins – 22 November 2025

Novo Nordisk Stock on 21 November 2025: NVO Slips as Denmark Grants Eye-Damage Payouts and GLP‑1 Price War Escalates

Pfizer Stock Today (PFE): mRNA Flu Breakthrough, $6B Metsera Bonds and a 7% Dividend – Nov. 21, 2025

Telomir Pharmaceuticals (TELO) Unveils Leukemia Breakthrough and Board Change – Full Investor Update for November 21, 2025

Pfizer Stock Today, November 20, 2025: Price Slide, Dividend Debate, Flu Shot Win and Texas Settlement

Moderna (MRNA) Sets 3‑Year mRNA Growth Plan After $1.5 Billion Loan and $140 Million U.S. Expansion – November 20, 2025

Psyence BioMed (NASDAQ: PBM) Jumps as It Secures Pharmaceutical‑Grade Ibogaine Supply for Global Clinical Trials – 20 November 2025

Novo Nordisk Stock Today (November 20, 2025): Wegovy Price Cuts, Alzheimer’s ‘Lottery Ticket’ Trials and Denmark GDP Put NVO Back in the Spotlight

RANI Stock Today (Nov 19, 2025): Rani Therapeutics slips to $1.75 as traders weigh October’s Chugai deal and year‑end catalysts

Agios Pharmaceuticals (AGIO) Stock Slides on Mixed Phase 3 Sickle Cell Results From RISE UP Trial

KVUE Stock Today (Nov. 18, 2025): Shares Slip as Appeals Court Weighs Tylenol Cases; Dividend Cleared; Kimberly‑Clark Deal Spread Persists

Arvinas (ARVN) Soars 14% as Investors Cheer Pipeline Reset and Jefferies Update

Novo Nordisk Stock Today (Nov 18, 2025): $199 Wegovy/Ozempic Intro Offer Drives Focus; Controlling Shareholder Sells ConvaTec Stake; NVO Edges Lower

Merck (MRK) Stock Today, Nov 18, 2025: Shares Jump on Winrevair Phase 2 Win as Cidara Deal Builds Flu Portfolio

Olema Pharmaceuticals (OLMA) Soars Over 200% After Roche Breast Cancer Trial Win — What It Means for Palazestrant and Investors on November 18, 2025

Pfizer (PFE) Stock Today, November 17, 2025: Migraine Drug Launch in India, Metsera Deal Closes and New RSV Vaccine Data

Tonix Pharmaceuticals (TNXP) Jumps as TONMYA, First New Fibromyalgia Drug in 15 Years, Hits U.S. Pharmacies – November 17, 2025

Galmed Pharmaceuticals (GLMD) Soars on New Cancer Drug Combo Data: What Today’s Breakthrough Means for Investors – November 17, 2025

Jazz Pharmaceuticals (JAZZ) Soars on Breakthrough Ziihera Phase 3 Results in Gastroesophageal Cancer – Key Updates for 17 November 2025

TechStock² Updates

H&R Block stock (HRB) surges 15% after share repurchases boost profit gains

ChipMOS stock (IMOS) climbs 12% after revenue hits record and margin jumps 11.4 points

On Holding Stock (ONON) Slides 20% as Americas Growth Slows

Microsoft stock (MSFT) retreats as Maia 300 launch challenges $116 billion capex investment

Lumentum (LITE) lifts margin forecast following revenue surge; targets 40% benchmark

Top Stock Picks

Taiwan Semiconductor

AerCap

Constellation Energy

Walt Disney

American International Group

Live updates

Investment Disclaimer